Archive

Tag: DOACs

Andexanet Alfa Vs. Four-Factor PCC: Is Andexanet Alfa Worth The Hype?

Background: Oral factor Xa inhibitors (FXi) have been associated with major and fatal bleeding events, including intracranial hemorrhage (ICH). In randomized controlled trials, both rivaroxaban and apixaban are associated with ICH at rates that range from 0.1 to 4% (Agnelli …

Read More
Hematology and OncologyNeurologyTrauma

Safety of PE Treatment with Rivaroxaban

Background: The simplified PE Severity Index (sPESI) is one of several validated prognostic tools for acute pulmonary embolism (PE).  The European Society of Cardiology recommended the use of the sPESI to risk-stratify patients with acute PE into low risk (sPESI=0) and …

Read More
Thoracic and Respiratory

Sponsored

0